Glaukos (GKOS) Competitors

Zimmer Biomet (NYSE:ZBH) and Glaukos (NYSE:GKOS) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends, media sentiment and valuation.

Is ZBH or GKOS more profitable?

Zimmer Biomet has a net margin of 10.51% compared to Glaukos' net margin of -21.43%. Zimmer Biomet's return on equity of 12.76% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zimmer Biomet	10.51%	12.76%	7.21%
Glaukos	-21.43%	-8.59%	-6.61%

Do insiders and institutionals have more ownership in ZBH or GKOS?

88.9% of Zimmer Biomet shares are owned by institutional investors. Comparatively, 99.0% of Glaukos shares are owned by institutional investors. 1.4% of Zimmer Biomet shares are owned by company insiders. Comparatively, 5.8% of Glaukos shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Which has more volatility & risk, ZBH or GKOS?

Zimmer Biomet has a beta of 0.68, meaning that its share price is 32% less volatile than the S&P 500. Comparatively, Glaukos has a beta of 0.78, meaning that its share price is 22% less volatile than the S&P 500.

Do analysts recommend ZBH or GKOS?

Zimmer Biomet presently has a consensus price target of $111.44, indicating a potential upside of 3.55%. Glaukos has a consensus price target of $127.42, indicating a potential upside of 35.25%. Given Glaukos' stronger consensus rating and higher possible upside, analysts plainly believe Glaukos is more favorable than Zimmer Biomet.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zimmer Biomet	2 Sell rating(s)	9 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.35
Glaukos	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.79

Which has stronger valuation and earnings, ZBH or GKOS?

Zimmer Biomet has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zimmer Biomet	$7.68B	2.78	$903.70M	$4.11	26.19
Glaukos	$432.95M	12.48	-$146.37M	-$1.65	-57.10

Does the media refer more to ZBH or GKOS?

In the previous week, Zimmer Biomet had 10 more articles in the media than Glaukos. MarketBeat recorded 24 mentions for Zimmer Biomet and 14 mentions for Glaukos. Zimmer Biomet's average media sentiment score of 1.48 beat Glaukos' score of 0.98 indicating that Zimmer Biomet is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zimmer Biomet	22 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Glaukos	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Zimmer Biomet beats Glaukos on 9 of the 17 factors compared between the two stocks.